Myelofibrosis patients face a grim clock. A new drug acquisition aims to change that.
PARIS — For patients with a certain type of myelofibrosis, the treatment road ends badly. Standard therapy works for a while. Then it stops.
The clock starts ticking. Median survival after that point?
One to two years. That brutal statistic is the hole Ipsen is trying to fill with its latest acquisition. The French pharmaceutical company announced it has signed a definitive agreement to buy Kartos Therapeutics, a private U.S. biotech based in Redwood City, California.
The deal hands Ipsen a late-stage drug called navtemadlin. The drug is an MDM2 inhibitor.
In plain terms, it is designed to restore the function of a protein called p53, which normally suppresses tumor growth. In myelofibrosis, that function gets switched off. Navtemadlin aims to switch it back on.
The target population is specific: patients with intermediate and high-risk TP53 wild-type myelofibrosis. That is medical shorthand for patients whose p53 gene is still intact but not working properly. These patients have had a suboptimal response to ruxolitinib, the current standard of care.
Ruxolitinib works well for many. It shrinks enlarged spleens.
It eases symptoms. But a significant proportion of patients do not get a good enough response. They discontinue treatment.
And after that, the data is clear: outcomes are dismal. That is the gap.
That is the patient group Kartos’s drug is meant to reach. Navtemadlin is not sitting on a shelf. It is already being tested in a global Phase III trial called POIESIS.
The trial is designed to enroll more than 600 patients across over 250 sites. The drug is being tested as an add-on therapy to standard care. That means patients already on ruxolitinib would get navtemadlin alongside it.
Ipsen’s CEO David Loew framed the deal as a pipeline move. He said the acquisition strengthens the company’s late-stage oncology pipeline.
He also said it reflects a continued focus on bringing transformational treatments to cancer patients. He expressed excitement about navtemadlin’s potential to define a new treatment paradigm. He called the current situation a critical care gap.
Loew also gave a timeline. A new therapeutic option could arrive as early as 2028.
For patients with a median survival of one to two years after standard therapy fails, that is not fast. But it is a target. Ipsen is headquartered in Paris.
It is listed on Euronext, with an ADR on the U.S. market. The company is buying a private U.S. biotech. The mechanics are straightforward.
The stakes are not. Myelofibrosis is a rare bone marrow cancer.
It causes scarring of the marrow. It leads to severe anemia, fatigue, and an enlarged spleen. For the patients who stop responding to ruxolitinib, options are few.
The clock runs. Navtemadlin is not a cure.
It is an attempt to buy time. To restore the body’s own tumor suppression. To give patients something after the standard option fails.
For the hundreds of patients enrolled in the POIESIS trial, and the thousands more who might follow, the drug represents a chance. A chance to shift that one-to-two-year survival curve. A chance to define a new treatment paradigm, as Loew put it.
That is the patient story behind the corporate deal. A company buys a drug.
A drug targets a protein. A protein controls a tumor suppressor. A tumor suppressor fails in myelofibrosis.
And patients run out of time. The acquisition is about filling that gap.
The question is whether navtemadlin can fill it before the clock runs out for those who need it most.
